BRILACIDIN FOR COVID-19 OVERVIEW UPDATED APRIL 20, 2020
Click here to download (pdf)
As conveyed across the last few weeks, Innovation has received inquiries asking about Brilacidin’s potential to treat the coronavirus (COVID-19) given the urgent worldwide need to find effective treatments for this deadly epidemic.
The linked PDF (click here), updated on March 1, is an informational overview summarizing the scientific rationale for Brilacidin as a potential coronavirus (COVID-19) treatment.
A dedicated email — covid19@ipharminc.com — has been set up by the Company to receive inbound inquiries regarding Brilacidin as a potential novel treatment for COVID-19.
The Company will keep shareholders apprised of news related to evaluating Brilacidin’s antiviral properties for potentially treating COVID-19, and other viruses, in addition to its core Brilacidin programs, in Ulcerative Colitis and Oral Mucositis.
